The pharmaceutical industry is at an inflection point. A major wave of pharmaceutical patents is expiring between 2025 and 2030, with 2026 marking a particularly sharp "patent cliff". Patents are expiring at an unprecedented rate, pricing pressure is mounting, and internally developed replacements are scarce. The question facing the industry's largest players is no longer whether their business model needs to change, but how fast and whether M&A is the vehicle that gets them there

The Patent Cliff and the Revenue Shock

When patents lapse, generics and biosimilars enter with lower prices, slashing sales of branded drugs. For small-molecule drugs, 90% of market share can vanish within months. Biologics hold up somewhat better, due to their complexity, but even they typically lose between 30% and 70% of sales in the first year alone.
 By 2030, this will have played out across 190 drugs, 69 of which are blockbusters generating over $1 billion a year. A Deloitte report (October 2024) about the ongoing patent cliff estimates that this represents roughly 46% of projected sales at risk for the ten largest pharmaceutical companies over the coming decade. This creates a fundamental challenge: pharmaceutical companies must replace large amounts of revenue in a short period of time.
 Leading the losses are drugs like Merck’s Keytruda, with $25 billion in 2023 sales, set to expire in 2028, and Bristol-Myers Squibb’s Eliquis, at $12 billion, due by 2027 or 2028. These hits will strain financials and R&D budgets, particularly for companies with weak pipelines. In general, eight of the 13 largest pharma firms, representing 55% of global market value, could see 30% or more of their revenue jeopardized.

The table highlights the strong dependence of some major companies on drugs nearing loss of exclusivity or that are already losing it. For firms such as Merck and BMS these figures are nearly half of the pharmaceutical revenues of the whole firm​

​Internal R&D is No Longer Enough
​
A logical response to this would be to invest in internal R&D. However, this is not sufficient. The development of a new drug is an enormously long, costly, risky process, with the average time to market exceeding 10 years and the financial investment often running into the billions of dollars. This explains why this event is so significant, it forces companies to prove that their business model is sustainable beyond a single product, that they have a robust, ongoing innovation pipeline to replace lost revenues.
 However, evidence shows how large pharmaceutical companies are no longer the primary source of drug innovation, instead they are increasingly its buyers. Between 2014 and 2023, the top 20 firms saw their share of FDA approvals plummet from 90% to 35%, and their contribution to first-in-class medicines fell from 82% to 35%. Today, it is smaller biotech companies that are generating the most meaningful scientific advances, while Big Pharma's competitive advantage lies in capital and deal-making, not discovery. Consequently, internal growth alone is structurally not capable of compensating for the revenue erosion, making external growth not only preferable but almost necessary.

​The Capital and Policy Tailwinds Behind M&A

In this perspective, Biopharma companies are entering 2026 with more dealmaking capacity than at any point in recent memory. EY puts that figure at up to $2.1 trillion, spanning cash reserves, debt headroom, and equity issuance potential; not committed capital, but a measure of just how much firepower the industry could bring to bear if it chose to. What makes this particularly significant is the growing pressure to actually deploy it. Patent cliffs, IRA-driven compression of revenue windows, and a widening growth gap are all pushing companies toward dealmaking, while financing conditions, though still elevated, have begun to ease. All the forces mentioned create a favourable environment and incentivize the growth possibilities through M&A.

The current macro and regulatory situation are reinforcing it. A first factor that could increase the number of consolidation deals is the possible interest rate cuts from the Fed. Even though the uncertainty caused by the middle east conflict and the high inflation has been delaying potential cuts, most forecasters have clung to the view that rates will fall at least once more.
In addition to this, the Trump administration has made several moves to make merger review less burdensome. For instance, the antitrust agencies have resumed the practice of granting early termination of the HSR waiting period and the FTC has expressed its intention to "get out of the way" of transactions that do not violate American law. Effectively reducing frictions and accelerating execution timelines.  

The IRA (Inflation Reduction Act) has put even more pressure on the pharmaceutical industry.  For the first time, the Secretary of Health and Human Services can negotiate a “Maximum Fair Price” (MFP) for high-expenditure Medicare drugs that lack generic or biosimilar competition and have been on the market beyond specified thresholds.
Finally, the threat and implementation of tariffs are further pushing companies to accelerate capital deployment and secure strategic assets domestically, reinforcing the urgency to lock in capabilities within the United States. A clear example is the pharmaceutical company Johnson & Johnson, which has announced it is planning to invest $55 billion in U.S. manufacturing.
Taken together, these forces not only support M&A, but they make it central in determining how the pharmaceutical companies will defend their growth and revenues over the coming decade.
​
That capital is already being deployed at a pace that is redefining what dealmaking looks like in the pharmaceutical industry. In the last 12 days of March 2026 alone, biopharma companies closed seven transactions each exceeding $1 billion, worth a combined $29 billion in headline value. It was the clearest signal yet that the M&A supercycle described in the previous section has moved from theory into execution. The question is no longer whether Big Pharma will buy, but rather what it is buying, where it is looking, and what the logic of each transaction reveals about where the industry is heading.

​The GLP-1 Arms Race

No single therapeutic area illustrates the current dealmaking fever more vividly than obesity and metabolic disease. The GLP-1 drug class, whose most prominent representatives include Novo Nordisk's semaglutide (GLP-1 receptor agonist used for type 2 diabetes and weight management) and Eli Lilly's Tirzepatide (active ingredient in medications as Mounjaro and Zepbound)  has generated, could become a $200 billion market, driven not by niche, high priced drugs, but by the prospect of widespread adoption at price points that health systems are increasingly willing to support. The scale of this opportunity has triggered an arms race among virtually every major pharmaceutical company, regardless of their historical positioning in this therapeutic area.
​
The defining moment came in late 2025, when Pfizer,  having previously failed in its own internal GLP-1 programme, entered into a bidding war with Novo Nordisk over Metsera (New York based clinical stage biopharmaceutical company), developing a longer acting, monthly dosed GLP-1 receptor agonist. Metsera initially agreed to a $4.9 billion upfront deal with Pfizer, before Novo Nordisk intervened with a $6.5 billion counteroffer. Pfizer ultimately prevailed, with the deal valued at up to $10 billion including milestone payments. The episode was significant not merely for its financial scale, but for what it revealed: even the company that pioneered semaglutide felt sufficiently threatened to bid billions for a competitor's next generation asset. More than 120 metabolic assets are currently in development across 60 companies, creating a deep pool of potential M&A targets. The competitive frontier has already shifted beyond injectable GLP-1s toward oral formulations, combination therapies, and once monthly dosing regimens, each representing a potential step change in patient adoption and therefore market share. Among the most closely watched assets is Structure Therapeutics' aleniglipron, an oral small molecule GLP-1 receptor agonist that delivered placebo adjusted weight loss of up to 15.3% in Phase 2b trials, with no plateau observed data that prompted immediate upward revisions to acquisition probability by sell side analysts. Viking Therapeutics, with its dual GLP-1/GIP receptor agonist VK2735 in both subcutaneous and oral formulations, similarly commands a Polymarket implied acquisition probability of roughly 25% before the end of 2026. The race has, in short, moved from "who has a GLP-1" to "who has the best oral, once monthly, or combination approach" and Big Pharma is willing to pay premium prices for anyone holding a credible answer.

​Beyond Obesity: The Broader Therapeutic Battleground

While GLP-1s dominate the headlines, they represent only one front in a broader M&A campaign spanning multiple therapeutic areas. Oncology, which has historically been the most active area for biopharma dealmaking, continues to drive the largest individual transactions. Among target areas, oncology accounted for 39% of total transaction volume in 2025, with a particular focus on precision oncology. Merck, facing the imminent loss of exclusivity on Keytruda, which generated $25 billion in sales in 2023, has executed three acquisitions exceeding $6 billion each over the past ten months alone, including a $9.2 billion deal for Cidara Therapeutics and a $6.7 billion acquisition of Terns Pharmaceuticals.
​
Antibody drug conjugates (ADCs) have emerged. These targeted therapies, which combine the precision of monoclonal antibodies with the cytotoxic potency of chemotherapy agents, have rapidly become among the most sought after assets in oncology dealmaking. Big Pharma's interest for more precisely targeted therapies has pushed ADC transactions to record levels, with smaller innovators generating much of the science and licensing activity. The strategic behind it is that ADCs offer the prospect of dramatically improved therapeutic windows relative to conventional chemotherapy, and the technology platform is broadly applicable across tumour types, making platform acquisitions particularly attractive to acquirers seeking durable competitive advantage rather than single indication exposure.

​The Chinese Wildcard

Perhaps the most structurally significant and underreported development in the current M&A cycle is the emergence of Chinese biotechnology companies as a primary source of licensable innovation for Western pharmaceutical firms. This represents a fundamental shift from China's historical role as a low cost manufacturing base and generics producer. By mid 2025, Western drugmakers had signed 14 licensing agreements worth up to $18.3 billion for Chinese assets,  up from just two deals in the same period of 2024  and by early 2026, 38 Chinese out licensing deals had already been announced. In the ADC space specifically, Chinese biotechs now account for nearly 90% of all global ADC licensing activity, with monoclonal antibody licensing from China jumping 43% to $11.3 billion in 2024.
​
Chinese biotechs are generating clinical data faster, at lower cost, and in therapeutic areas, particularly oncology, where they have developed genuine scientific leadership. Deals involving Chinese pharma and biotech firms reached $92.2 billion in potential value through November 2025, nearly double the $51.9 billion recorded in the whole of 2024. 
However, accessing Chinese drug portfolios is not without risk as Western companies must carefully navigate growing geopolitical tensions, structuring deals to protect their intellectual property while maintaining political flexibility, in what amounts to a high stakes trade off between short term portfolio gains and long term political exposure.

​The New M&A Criteria

Understanding which assets are being acquired and at what valuations reveals a dealmaking logic that define the current M&A cycle. Unlike the pandemic era boom, when capital flowed toward early stage platform companies, today's acquirers target assets with late stage clinical data, regulatory clarity, and clean intellectual property. As one former Director at Johnson & Johnson noted, companies are seeking assets where "clean IP and regulatory clarity" are in place  with companies lacking strong patent portfolios facing valuation discounts of 30 to 50% relative to peers with robust IP protection.
​
This shows how strategic pharma deal value jumped 79% through November 2025 while the average deal size rose over 80%. Therefore the dealmaking activity of the past eighteen months reveals an industry engaged in nothing less than a structural reorganisation of where pharmaceutical innovation is sourced, financed, and ultimately owned. The patent cliff has created the necessity, the $2.1 trillion in available firepower has created the means and the convergence of obesity, oncology, and Chinese innovation has pointed them in the right direction. What remains to be seen is what all of this means for capital markets, for biotech valuations, and for the investors who are now asking whether the best buying opportunity in a decade has already passed.

​From Trading Below Cash to the Biggest IPO Boom in Years

The most compelling feature of the current biotech cycle is not simply the scale of pharmaceutical M&A, but the valuation dislocation that preceded it. After the pandemic era boom of 2020 and 2021, biotech entered a severe three year correction. Capital dried up, risk appetite collapsed, and equity markets aggressively repriced the sector. By mid 2025, nearly half of all publicly listed US biotech companies were trading below the level of cash on their balance sheets, an extraordinary signal that the market was assigning little to no value to pipelines, intellectual property, and future innovation.

This dislocation was not driven by a collapse in science, but by a shift in capital markets. Higher interest rates increased the cost of funding long duration assets, while generalist investors rotated away from speculative growth. The XBI biotech index fell sharply, with the April 2025 tariff shock acting as a final catalyst that pushed valuations to distressed levels. For specialist investors, this created a rare entry point where downside appeared limited relative to long term upside.

What followed was not a broad based recovery, but a clear separation between winners and losers. Weaker companies, particularly those without meaningful clinical progress, struggled to access capital and in many cases became stranded. In contrast, higher quality biotechs with credible data and differentiated science became deeply attractive acquisition targets. The capital winter effectively acted as a filter, strengthening the survivors and making them more valuable to strategic buyers.
​
This dynamic set in motion a self reinforcing cycle between M&A and capital markets. When large pharmaceutical companies acquire biotech firms, the proceeds do not leave the system. Venture capital investors, crossover funds, and public shareholders who receive cash from deals typically redeploy that capital into new opportunities. Transactions such as Merck’s acquisition of Terns Pharmaceuticals and Eli Lilly’s purchase of Centessa illustrate this clearly. These deals are not just endpoints, they are mechanisms that recycle capital back into the ecosystem.

​How M&A Recycles Capital Into New Opportunities

There is also a direct mechanical link between M&A activity and IPO markets. Late stage biotech companies often run a dual track process, exploring acquisition offers while preparing for a public listing. As acquisition activity increases and valuations rise, it establishes a benchmark for public market pricing. In this way, strong deal flow does not just absorb supply, it actively encourages more companies to come to market. The current M&A cycle is therefore reopening the broader capital markets pipeline.

That reopening is already visible. After falling to the lowest level in over a decade, US biotech IPO activity has begun to recover meaningfully. In early 2026, more companies have gone public at valuations above 500 million dollars than in the whole of 2025. In February alone, four biotech companies raised 1.2 billion dollars in just three days. This marks a clear shift in sentiment, but it is important to recognise that this cycle looks very different from 2021.

The previous boom rewarded early stage companies with limited clinical validation. Today, investors are far more selective. Capital is flowing toward companies with clinical proof of concept, differentiated mechanisms, and clear paths to commercialisation. The market has moved from narrative driven investing to data driven capital allocation. This creates a healthier IPO environment, but one where access to funding is highly uneven.

For investors, this results in a highly asymmetric opportunity set. On one side, the structural backdrop remains extremely supportive. Pharmaceutical companies have an estimated 1.4 trillion dollars of capital available for dealmaking, while thousands of patents are set to expire by 2030, ensuring sustained demand for external innovation. At the same time, biotech valuations in many areas remain below pre 2021 levels, suggesting that the full impact of this cycle may not yet be reflected in prices.
​
On the other side, the risks are becoming more specific and harder to ignore. Regulatory uncertainty around FDA processes can delay approvals and impact valuations. Trade policy and tariffs introduce additional complexity for companies with international manufacturing exposure. Perhaps most importantly, the strongest assets are already attracting premium valuations, raising the risk that future returns are being pulled forward.

​A Market With Uneven Rewards

Success in this environment is therefore not evenly distributed. Capital is concentrating in a narrow group of companies with strong clinical data, robust intellectual property, and near term commercial potential. Earlier stage companies without clear catalysts continue to struggle for attention. This divergence highlights the central reality of the current market, it is not a broad recovery, but a selective repricing of quality.
​
The key question for investors is whether the opportunity has already been captured or whether this is the beginning of a longer cycle. The answer likely lies in understanding that this is not a single moment, but an ongoing process. As long as large pharmaceutical companies remain dependent on external innovation to replace lost revenues, demand for high quality biotech assets will persist.
In that sense, the current environment is less about timing the bottom and more about positioning for a multi year cycle driven by capital recycling, consolidation, and selective growth. The opportunity is real, but it requires discipline and a clear understanding of the underlying mechanics.

​Conclusion

The patent cliff is not just a revenue shock, it is forcing a structural reset in how the pharmaceutical industry innovates, allocates capital, and competes. Faced with unprecedented losses and limited internal solutions, large pharma has turned decisively toward acquisition as its primary engine of growth. This has triggered a powerful M and A cycle that is reshaping the entire biotech ecosystem, from early stage innovation to public market dynamics.

What makes this moment particularly significant is the interaction between industry necessity and market opportunity. The same forces that created distress across biotech have also laid the foundation for one of the most compelling investment environments in years. Capital is flowing again, IPO markets are reopening, and high quality assets are being repriced as strategic demand accelerates.
However, this is not a broad based recovery. It is a selective and disciplined cycle, where capital concentrates in companies with real science, strong intellectual property, and clear commercial pathways. The result is a market that rewards quality and punishes uncertainty, creating both opportunity and risk for investors.
​
Ultimately, the patent cliff has done more than trigger a wave of deals. It has redefined the relationship between pharma and biotech, turning innovation into a traded asset class and M and A into the central mechanism of industry evolution. Whether this proves to be the start of a sustained supercycle or a shorter window of opportunity will depend on how long these structural forces persist. What is clear is that the cycle is already underway, and those who understand its mechanics will be best positioned to benefit from it.

By Stefaniya Yakubovskaya, Tristan Buckley, Pietro Nicolazzi

​Sources

• Reuters
• PWC
• Deloitte
• GeneOnline
• DrugPatentWatch

• CBS News